A Tyr Pharma Inc - Understand $atyr stock

$ATYR Market Cap: $137.9 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$588.0K

TTM

Gross Margin

Net Earnings

-$57.86M

TTM

Current Assets

$90.30M

Q2 2024

Current Liabilities

$11.84M

Q2 2024

Current Ratio

762.84%

Q2 2024

Total Assets

$105.9M

Q2 2024

Total Liabilities

$24.33M

Q2 2024

Book Value

$81.61M

Q2 2024

Cash

$6.805M

Q2 2024

P/E

-2.384

Sep 18, 2024 EST

Free Cash Flow

-$64.05M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Revenue	$353.0K	$10.39M	$0.00	$10.46M	$422.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	-96.6%		-100.0%	2378.67%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Revenue	$353.0K	$10.39M	$0.00	$10.46M	$422.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Selling, General & Admin	$12.98M	$13.98M	$10.75M	$9.080M	$9.350M	$12.44M	$17.08M	$15.09M	$13.11M	$6.780M	$5.710M	$4.850M
YoY Change	-7.17%	30.05%	18.4%	-2.89%	-24.84%	-27.17%	13.19%	15.1%	93.36%	18.74%	17.73%
% of Gross Profit
Research & Development	$42.29M	$42.81M	$23.26M	$17.29M	$14.05M	$20.39M	$30.07M	$42.85M	$34.50M	$16.78M	$13.83M	$7.750M
YoY Change	-1.2%	84.01%	34.54%	23.09%	-31.09%	-32.2%	-29.83%	24.18%	105.66%	21.29%	78.48%
% of Gross Profit
Depreciation & Amortization	$592.0K	$200.0K	$500.0K	$600.0K	$600.0K	$746.0K	$713.0K	$900.0K	$869.0K	$829.0K	$714.0K	$540.0K
YoY Change	196.0%	-60.0%	-16.67%	0.0%	-19.57%	4.63%	-20.78%	3.57%	4.83%	16.11%	32.22%
% of Gross Profit
Operating Expenses	$55.27M	$56.79M	$34.02M	$26.37M	$23.40M	$20.39M	$47.15M	$57.94M	$47.62M	$23.55M	$19.54M	$12.60M
YoY Change	-2.67%	66.96%	29.01%	12.68%	14.79%	-56.76%	-18.63%	21.68%	102.16%	20.53%	55.1%
Operating Profit	-$54.92M	-$46.40M	-$34.02M	-$15.91M	-$22.98M		-$47.15M	-$57.94M	-$47.62M	-$23.55M	-$19.54M
YoY Change	18.35%	36.42%	113.78%	-30.76%			-18.63%	21.68%	102.16%	20.53%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Interest Expense								$65.00K	-$386.0K	-$832.0K	-$444.0K	-$270.0K
YoY Change								-116.84%	-53.61%	87.39%	64.44%
% of Operating Profit
Other Income/Expense, Net	$4.522M	$1.061M	$238.0K	-$319.0K	-$785.0K	-$1.700M	-$1.062M	$36.00K	-$357.0K	-$796.0K	-$472.0K
YoY Change	326.2%	345.8%	-174.61%	-59.36%	-53.82%	60.08%	-3050.0%	-110.08%	-55.15%	68.64%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Pretax Income	-$50.40M	-$45.34M	-$33.77M	-$16.23M	-$23.76M	-$34.52M	-$48.21M	-$57.90M	-$47.97M	-$24.35M	-$20.01M	-$12.86M
YoY Change	11.15%	34.25%	108.1%	-31.7%	-31.15%	-28.4%	-16.75%	20.7%	97.01%	21.66%	55.63%
Income Tax	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	-$49.00K
% Of Pretax Income
Net Earnings	-$50.39M	-$45.34M	-$33.77M	-$16.22M	-$23.60M	-$34.52M	-$48.21M	-$57.86M	-$47.97M	-$24.35M	-$20.01M	-$12.86M
YoY Change	11.14%	34.26%	108.14%	-31.26%	-31.62%	-28.4%	-16.68%	20.6%	97.01%	21.66%	55.63%
Net Earnings / Revenue	-14274.5%	-436.53%		-155.11%	-5593.13%
Basic Earnings Per Share	-$0.94	-$1.60	-$1.77	-$1.77
Diluted Earnings Per Share	-$0.94	-$1.60	-$1.770M	-$1.771M	-$7.024M	-$16.13M	-$26.20M	-$34.24M	-$28.38M	-$15.12M	-$12.43M	-$7.988M

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Cash & Short-Term Investments	$98.17M	$66.15M	$107.9M	$31.70M	$31.10M	$49.50M	$85.10M	$72.10M	$95.50M	$15.90M	$36.50M	$3.700M
YoY Change	48.41%	-38.7%	240.41%	1.93%	-37.17%	-41.83%	18.03%	-24.5%	500.63%	-56.44%	886.49%
Cash & Equivalents	$22.54M	$9.981M	$2.336M	$17.00M	$9.200M	$23.00M	$21.10M	$38.40M	$53.00M	$13.90M	$36.50M	$3.700M
Short-Term Investments	$75.62M	$56.17M	$105.6M	$14.70M	$21.90M	$26.60M	$64.00M	$33.80M	$42.50M	$2.000M	$0.00	$0.00
Other Short-Term Assets	$2.390M	$2.950M	$5.223M	$1.800M	$800.0K	$1.300M	$1.900M	$2.600M	$2.400M	$700.0K	$600.0K	$800.0K
YoY Change	-18.98%	-43.52%	190.17%	125.0%	-38.46%	-31.58%	-26.92%	8.33%	242.86%	16.67%	-25.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$103.0M	$80.87M	$113.6M	$35.50M	$31.90M	$50.80M	$87.00M	$74.80M	$98.00M	$16.50M	$37.00M	$4.500M
YoY Change	27.35%	-28.79%	219.91%	11.29%	-37.2%	-41.61%	16.31%	-23.67%	493.94%	-55.41%	722.22%
Property, Plant & Equipment	$14.05M	$11.56M	$1.810M	$3.000M	$4.100M	$1.900M	$2.300M	$1.400M	$1.800M	$1.900M	$2.500M	$2.600M
YoY Change	21.54%	538.51%	-39.67%	-26.83%	115.79%	-17.39%	64.29%	-22.22%	-5.26%	-24.0%	-3.85%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments							$0.00	$4.000M	$29.80M
YoY Change							-100.0%	-86.58%
Other Assets	$3.615M	$3.358M	$158.0K	$200.0K	$200.0K	$100.0K	$100.0K	$300.0K	$100.0K	$2.200M	$300.0K	$300.0K
YoY Change	7.65%	2025.32%	-21.0%	0.0%	100.0%	0.0%	-66.67%	200.0%	-95.45%	633.33%	0.0%
Total Long-Term Assets	$17.66M	$14.92M	$1.968M	$3.200M	$4.300M	$1.900M	$2.400M	$5.700M	$31.70M	$4.100M	$2.800M	$2.900M
YoY Change	18.41%	657.88%	-38.5%	-25.58%	126.32%	-20.83%	-57.89%	-82.02%	673.17%	46.43%	-3.45%
Total Assets	$120.7M	$95.79M	$115.5M	$38.70M	$36.20M	$52.70M	$89.40M	$80.50M	$129.7M	$20.60M	$39.80M	$7.400M
YoY Change
Accounts Payable	$3.529M	$3.106M	$1.031M	$1.400M	$800.0K	$1.000M	$2.300M	$2.600M	$3.900M	$1.400M	$1.100M	$600.0K
YoY Change	13.62%	201.26%	-26.36%	75.0%	-20.0%	-56.52%	-11.54%	-33.33%	178.57%	27.27%	83.33%
Accrued Expenses	$12.39M	$10.49M	$4.982M	$4.400M	$3.100M	$2.000M	$3.100M	$5.500M	$4.600M	$2.900M	$2.900M	$1.800M
YoY Change	18.09%	110.6%	13.23%	41.94%	55.0%	-35.48%	-43.64%	19.57%	58.62%	0.0%	61.11%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$497.0K	$264.0K		$0.00	$8.700M	$7.800M	$5.000M	$300.0K	$3.400M	$5.100M	$700.0K	$800.0K
YoY Change	88.26%			-100.0%	11.54%	56.0%	1566.67%	-91.18%	-33.33%	628.57%	-12.5%
Total Short-Term Liabilities	$16.42M	$13.86M	$6.013M	$5.900M	$12.90M	$10.80M	$10.40M	$8.500M	$12.10M	$10.10M	$5.200M	$3.500M
YoY Change	18.42%	130.53%	1.92%	-54.26%	19.44%	3.85%	22.35%	-29.75%	19.8%	94.23%	48.57%
Long-Term Debt	$1.428M	$1.007M	$0.00	$0.00	$0.00	$8.300M	$14.70M	$9.200M	$1.800M	$5.100M	$6.200M	$3.700M
YoY Change	41.81%				-100.0%	-43.54%	59.78%	411.11%	-64.71%	-17.74%	67.57%
Other Long-Term Liabilities	$12.34M	$9.633M	$398.0K	$1.400M	$2.200M			$0.00	$700.0K	$800.0K	$1.300M	$1.500M
YoY Change	28.09%	2320.35%	-71.57%	-36.36%				-100.0%	-12.5%	-38.46%	-13.33%
Total Long-Term Liabilities	$13.77M	$10.64M	$398.0K	$1.400M	$2.200M	$8.300M	$14.70M	$9.200M	$2.500M	$5.900M	$7.500M	$5.200M
YoY Change	29.39%	2573.37%	-71.57%	-36.36%	-73.49%	-43.54%	59.78%	268.0%	-57.63%	-21.33%	44.23%
Total Liabilities	$30.00M	$24.32M	$6.236M	$7.100M	$15.00M	$19.10M	$25.10M	$17.70M	$14.60M	$16.00M	$15.10M	$8.800M
YoY Change	23.32%	290.03%	-12.17%	-52.67%	-21.47%	-23.9%	41.81%	21.23%	-8.75%	5.96%	71.59%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020
Basic Shares Outstanding	53.61M	28.42M	19.08M	9.160M
Diluted Shares Outstanding	53.61M	28.42M	19.08M	9.160M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Dividends

Stock Price

Market Cap: $137.95 Million

About aTyr Pharma Inc

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. The company is headquartered in San Diego, California and currently employs 56 full-time employees. The company went IPO on 2015-05-07. The firm is leveraging intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0101 binds directly to latent-transforming growth factor beta-binding protein 1 (LTBP1), which regulates transforming growth factor beta (TGFb). Its ATYR0750 is a fusion protein derived from a domain of alanyl-tRNA synthetase (AARS).

Industry: Biological Products, (No Diagnostic Substances) Peers: Assembly Biosciences Inc Gelesis Holdings Inc Surrozen Inc Fortress Biotech Inc Cue Biopharma Inc Finch Therapeutics Group Inc HOOKIPA Pharma Inc Pieris Pharmaceuticals Inc Xilio Therapeutics Inc